124 related articles for article (PubMed ID: 11418530)
1. Comparative in vitro study of the activity of moxifloxacin and other antibiotics against 150 strains of penicillin non-susceptible Streptococcus pneumoniae and against 110 strains of ampicillin-resistant Haemophilus influenzae isolated in 1999-2000 in Spain.
Alós JI; Oteo J; Aracil B; Gómez-Garcés JL
J Antimicrob Chemother; 2001 Jul; 48(1):145-8. PubMed ID: 11418530
[No Abstract] [Full Text] [Related]
2. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
3. Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Lopez H; Vilches V; Scarano S; Stepanik D; Smayevsky J; Lemme L; Cardeñosa O; Ambler J; Sucari A
Int J Antimicrob Agents; 2001 Oct; 18(4):379-82. PubMed ID: 11691572
[TBL] [Abstract][Full Text] [Related]
4. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.
Brueggemann AB; Kugler KC; Doern GV
Antimicrob Agents Chemother; 1997 Jul; 41(7):1594-7. PubMed ID: 9210692
[TBL] [Abstract][Full Text] [Related]
6. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
7. [In vitro activity of moxifloxacin against respiratory pathogens in Latin America].
López H; Sader H; Amábile C; Pedreira W; Muñoz Bellido JL; García Rodríguez JA;
Rev Esp Quimioter; 2002 Dec; 15(4):325-34. PubMed ID: 12587037
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
9. National surveillance programme on susceptibility patterns of respiratory pathogens in South Africa: moxifloxacin compared with eight other antimicrobial agents.
Liebowitz LD; Slabbert M; Huisamen A
J Clin Pathol; 2003 May; 56(5):344-7. PubMed ID: 12719453
[TBL] [Abstract][Full Text] [Related]
10. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
11. Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.
Hermsen ED; Hovde LB; Konstantinides GN; Rotschafer JC
Antimicrob Agents Chemother; 2005 Apr; 49(4):1633-5. PubMed ID: 15793158
[TBL] [Abstract][Full Text] [Related]
12. Bactericidal properties of moxifloxacin and post-antibiotic effect.
Boswell FJ; Andrews JM; Wise R; Dalhoff A
J Antimicrob Chemother; 1999 May; 43 Suppl B():43-9. PubMed ID: 10382875
[TBL] [Abstract][Full Text] [Related]
13. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
14. [National multicenter study of the in vitro activity of moxifloxacin against respiratory tract pathogens. Spanish Study Group on Moxifloxacin].
Loza E; Morosini M; Negri MC; Almaraz F; Cantón R; Baquero F
Rev Esp Quimioter; 2000 Mar; 13(1):37-43. PubMed ID: 10855023
[TBL] [Abstract][Full Text] [Related]
15. Bactericidal activity of moxifloxacin against pneumococci.
Levy D; Berche P
Clin Microbiol Infect; 2001 Jan; 7(1):47-8. PubMed ID: 11284948
[No Abstract] [Full Text] [Related]
16. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
17. Penicillin-resistant streptococcus pneumoniae: review of moxifloxacin activity.
Dalhoff A; Krasemann C; Wegener S; Tillotson G
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S22-9. PubMed ID: 11249825
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity of older and newer fluoroquinolones against respiratory tract pathogens.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2000; 46(5):309-14. PubMed ID: 10965095
[TBL] [Abstract][Full Text] [Related]
19. Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
Johnson AP; Warner M; George RC; Livermore DM
J Antimicrob Chemother; 2001 Apr; 47(4):411-5. PubMed ID: 11266412
[TBL] [Abstract][Full Text] [Related]
20. Calculation of composite recovery time: a new pharmacodynamic parameter.
MacKenzie FM; Milne KE; Gould IM
J Antimicrob Chemother; 2002 Aug; 50(2):281-4. PubMed ID: 12161413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]